Statement: the primary trial designates specific interventions to its patients depending on their hormone status, Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients, in contrast the secondary trial assigns interventions randomly.
Primary_evidence: INTERVENTION 1:    Cohort A: Triple-negative Breast Cancer Patients   Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route. INTERVENTION 2:    Cohort B: ER/PR Positive/HER2-negative Breast Cancer Patients   Patients with hormone receptor positive (ER and/or PR positive), HER negative breast cancer breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route.
Secondary_evidence: INTERVENTION 1:    Laser Therapy Alone   therapist administered laser treatment   laser: therapist administered laser INTERVENTION 2:    Mld Alone   therapist administered manual lymphatic drainage   manual lymphatic drainage: therapist administered massage therapy